All In Biotech

Drug Trial Radar · NCT05838066

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

A Randomized, Controlled, Open-label, Multicenter, Phase Ш Clinical Study of the Efficacy and Safety of KN026 in Combination With HB1801 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

Last checked: Nov 19, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 880 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

880

Planned (sponsor's estimate)

Start

Jul 23, 2023

Primary completion

Jul 31, 2025

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
May 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, open-label, multicenter, phase Ш clinical study designed to compare the efficacy and safety of KN026 in combination with HB1801 to trastuzumab in combination with pertuzumab and docetaxel in the first-line treatment of subjects with HER2-positive recurrent or metastatic breast cancer. The statistical assumption for this study is superiority. The primary study endpoint was PFS as assessed by Blinded Independ Review Committee (BIRC).

Conditions

  • First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer

Interventions

  • Recombinant Humanized Bispecific antibody against HER2,KN026Drug

    IV infusion

  • HB1801Drug

    IV infusion

  • PertuzumabDrug

    840 mg loading dose followed by 420 mg per cycle, D1 Q3W, IV infusion

  • TrastuzumabDrug

    8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion

  • DocetaxelDrug

    75 mg/m\^2, D1 Q3W, IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Free-progression survival (PFS) as evaluated by BIRC (RECIST1.1).Time frame: Up to approximately 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trials Information Group

    Beijing, chaoyang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.